Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophy-associated progeroid syndrome due to an LMNA variant: A case report

J Diabetes Investig. 2022 Sep;13(9):1636-1638. doi: 10.1111/jdi.13827. Epub 2022 Jun 10.

Abstract

Leptin replacement therapy (LRT) has drastically improved the prognosis of patients with lipodystrophy, but pro-inflammatory properties of leptin could become evident in the long term. Here, we report a 30-year-old Japanese woman with generalized lipodystrophy-associated progeroid syndrome due to a heterozygous LMNA variant (c.29C > T; p.T10I), who was diagnosed with severe aortic stenosis (AS) after more than a decade of LRT, which required transcatheter aortic valve implantation. Given her marked hypoadiponectinemia and the LMNA variant, our patient might have been susceptible to progeria-associated disorders, including aortic stenosis, which could have been exaggerated by the prolonged 'imbalanced adipokines' caused by LRT between pro-inflammatory leptin and anti-inflammatory adiponectin. Thus, long-term LRT could be associated with AS in patients with the LMNA variant to cause generalized lipodystrophy-associated progeroid syndrome and hypoadiponectinemia.

Keywords: Adiponectin; Generalized lipodystrophy-associated progeroid syndrome; Leptin replacement therapy.

Publication types

  • Case Reports

MeSH terms

  • Adiponectin / deficiency
  • Adult
  • Aortic Valve Stenosis* / complications
  • Aortic Valve Stenosis* / surgery
  • Female
  • Humans
  • Lamin Type A / genetics
  • Leptin
  • Lipodystrophy* / complications
  • Lipodystrophy* / diagnosis
  • Lipodystrophy, Congenital Generalized* / complications
  • Metabolism, Inborn Errors

Substances

  • Adiponectin
  • LMNA protein, human
  • Lamin Type A
  • Leptin

Supplementary concepts

  • Hypoadiponectinemia

Grants and funding